Glucose-Dementia Association Is Consistent Over Blood Pressure/Antihypertensive Groups.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2021
Historique:
pubmed: 9 2 2021
medline: 14 9 2021
entrez: 8 2 2021
Statut: ppublish

Résumé

Higher glucose levels are associated with dementia risk in people with and without diabetes. However, little is known about how this association might vary by hypertension status and antihypertensive treatment. Most studies on modifiable dementia risk factors consider each factor in isolation. To test the hypothesis that hypertension and antihypertensive treatments may modify associations between glucose levels and dementia. Analyses of data generated from a research study and clinical care of participants from a prospective cohort of dementia-free older adults, including glucose measures, diabetes and antihypertensive treatments, and blood pressure data. We defined groups based on blood pressure (hypertensive versus not, ≥140/90 mmHg versus <140/90 mmHg) and antihypertensive treatment intensity (0, 1, or ≥2 classes of antihypertensives). We used Bayesian joint models to jointly model longitudinal exposure and time to event data. A total of 3,056 participants without diabetes treatment and 480 with diabetes treatment were included (mean age at baseline, 75.1 years; mean 7.5 years of follow-up). Higher glucose levels were associated with greater dementia risk among people without and with treated diabetes. Hazard ratios for dementia were similar across all blood pressure/antihypertensive treatment groups (omnibus p = 0.82 for people without and p = 0.59 for people with treated diabetes). Hypertension and antihypertensive treatments do not appear to affect the association between glucose and dementia risk in this population-based longitudinal cohort study of community-dwelling older adults. Future studies are needed to examine this question in midlife and by specific antihypertensive treatments.

Sections du résumé

BACKGROUND
Higher glucose levels are associated with dementia risk in people with and without diabetes. However, little is known about how this association might vary by hypertension status and antihypertensive treatment. Most studies on modifiable dementia risk factors consider each factor in isolation.
OBJECTIVE
To test the hypothesis that hypertension and antihypertensive treatments may modify associations between glucose levels and dementia.
METHODS
Analyses of data generated from a research study and clinical care of participants from a prospective cohort of dementia-free older adults, including glucose measures, diabetes and antihypertensive treatments, and blood pressure data. We defined groups based on blood pressure (hypertensive versus not, ≥140/90 mmHg versus <140/90 mmHg) and antihypertensive treatment intensity (0, 1, or ≥2 classes of antihypertensives). We used Bayesian joint models to jointly model longitudinal exposure and time to event data.
RESULTS
A total of 3,056 participants without diabetes treatment and 480 with diabetes treatment were included (mean age at baseline, 75.1 years; mean 7.5 years of follow-up). Higher glucose levels were associated with greater dementia risk among people without and with treated diabetes. Hazard ratios for dementia were similar across all blood pressure/antihypertensive treatment groups (omnibus p = 0.82 for people without and p = 0.59 for people with treated diabetes).
CONCLUSION
Hypertension and antihypertensive treatments do not appear to affect the association between glucose and dementia risk in this population-based longitudinal cohort study of community-dwelling older adults. Future studies are needed to examine this question in midlife and by specific antihypertensive treatments.

Identifiants

pubmed: 33554906
pii: JAD201138
doi: 10.3233/JAD-201138
doi:

Substances chimiques

Antihypertensive Agents 0
Blood Glucose 0
Glycated Hemoglobin A 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

79-90

Auteurs

Jing Zhou (J)

Kaiser Permanente Health Research Institute, Seattle, WA, USA.

Rod L Walker (RL)

Kaiser Permanente Health Research Institute, Seattle, WA, USA.

Shelly L Gray (SL)

Departments of Pharmacy, University of Washington, Seattle, WA, USA.

Zachary A Marcum (ZA)

Departments of Pharmacy, University of Washington, Seattle, WA, USA.

Douglas Barthold (D)

Departments of Pharmacy, University of Washington, Seattle, WA, USA.

James D Bowen (JD)

Department of Neurology, Swedish Hospital Medical Center, Seattle, WA, USA.

Wayne McCormick (W)

Department of Medicine, University of Washington, Seattle, WA, USA.

Susan M McCurry (SM)

Departments of Psychosocial and Community Health, University of Washington, Seattle, WA, USA.

Eric B Larson (EB)

Kaiser Permanente Health Research Institute, Seattle, WA, USA.

Paul K Crane (PK)

Department of Medicine, University of Washington, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH